Malaria
Conditions
Interventions
Mass Screening And Treatment
Insecticide residual spraying
MSAT
IRS+MDA
Control
Sponsors
Universite Cheikh Anta Diop, Dakar
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In each year of intervention, hotspot areas will be defined on the basis of the previous year¿s malaria cases. Within the hotspots in the intervention clusters, all households will be offered IRS spraying, and all persons over 3 months of age will be included in MDA and MSAT rounds. For the cross sectional survey each year, participants (all ages, both genders) will be selected randomly from the DSS database, all selected persons who consent to participate will be included. Pregnant women will be eligible for treatment with DHA-PQ if they are in the second or third trimester (more than 3 months since last menstrual period, or after quickening (first movements of the baby detected by the mother).
Exclusion criteria
Exclusion criteria: Health posts in urban and semi-urban areas will be excluded. Households will be excluded from IRS if the head of the household does not consent. They will remain eligible for other aspects of the trial. In MDA and MSAT arms, households will not be included if the head of the household refuses. Individuals will be included only if they (or their mother/carer) consent. In the MDA arm of the trial, treatment with DHA-PQ will be withheld from babies under 3 months of age, from person with history of allergy to ACTs, from persons who are unwell and require medical attention, and from women who say they are pregnant. Persons who are unwell will be referred to the nearest health facility. In the MSAT arm, babies under 3 months of age will not be screened. Women in the first trimester of pregnancy (pregnant for less than 3 months) and women who believe they may be pregnant, who test positive for malaria by RDT, and persons with known allergy to ACTs who test positive by RDT, will not be treated with DHA-PQ, they will be given a referral card with their test result and referred for treatment at the nearest health post. Persons who are unwell with fever will be tested and treated with DHA-PQ if positive, or referred, in accordance with national guidelines for community case
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of malaria infection and incidence of malaria in year 2 | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of malaria infection in the hotspots;Incidence of malaria and prevalence of malaria infection in targetted and non-targetted areas in year 1 and year 2;Incidence of severe adverse events within 10 days of drug administration;Coverage of and adherence to the interventions;The prevalence of molecular markers associated with resistance to PQ;Costs of the interventions;Prevalence of infection by PCR and prevalence by serology | — |
Countries
Senegal
Contacts
Public ContactPaul;Oumar Milligan;Gaye
Reader LSHTM;Professor UCAD
Outcome results
None listed